Valencia, Calif-based Bioness Inc announces that its StimRouter Neuromodulation System is currently being implanted successfully in patients at clinical institutions across the country to treat chronic pain.
The FDA-cleared, minimally invasive, patient-controlled system is designed to specifically target chronic pain that originates in the peripheral nerve. Its aim is to be a cost-effective alternative to injections, ongoing medication regimens, and complex surgeries.
Among the specific focus areas currently being treated via implantation of the StimRouter system are: Axillary nerve (eg, post-stroke shoulder pain), Ulnar nerve (eg, cubital tunnel syndrome), Ilioinguinal (eg, post-surgical hernia complication), and Superior Cluneal nerve (eg, lower back neuralgia).
“As clinicians and patients continue to look for effective and sustainable ways to treat and manage pain, it is rewarding to see patients thrive with our StimRouter technology,” shares Todd Cushman, president and CEO of Bioness, in a media release from the company. “Pain is more than just a barrier to a comfortable life and pursing employment, it can be what prevents patients from being able to seek therapy to rehabilitate an injury or illness.”
“As hard as it is to understand the impact of one’s pain, it is easy to see when relief is delivered,” says William Porter McRoberts, MD, a trained Physiatrist and Interventional Spine and Pain Management Specialist based in Fort Lauderdale, Florida, in the release.
“I’m very pleased with how well my patients are responding to the StimRouter and believe that the technology will be suitable for a greater range of patients in the future,” he adds.
[Source(s): Bioness Inc, PR Newswire]